X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (119) 119
index medicus (99) 99
hematology (87) 87
hemic and lymphatic diseases (79) 79
female (63) 63
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (63) 63
adult (62) 62
male (62) 62
leukemia, myelogenous, chronic, bcr-abl positive - genetics (59) 59
middle aged (58) 58
oncology (57) 57
imatinib (55) 55
aged (54) 54
fusion proteins, bcr-abl - genetics (53) 53
chronic myelogenous leukemia (52) 52
chronic myeloid leukemia (52) 52
imatinib mesylate (51) 51
protein kinase inhibitors - therapeutic use (51) 51
antineoplastic agents - therapeutic use (40) 40
pyrimidines - therapeutic use (40) 40
benzamides (37) 37
treatment outcome (37) 37
adolescent (32) 32
dasatinib (32) 32
piperazines - therapeutic use (32) 32
leukemia (30) 30
mutation (29) 29
chronic myeloid-leukemia (28) 28
resistance (28) 28
bcr-abl (25) 25
young adult (25) 25
drug resistance, neoplasm - genetics (24) 24
tyrosine kinase inhibitors (24) 24
nilotinib (23) 23
prognosis (23) 23
tyrosine (23) 23
aged, 80 and over (22) 22
cancer (22) 22
therapy (22) 22
genetic aspects (20) 20
abridged index medicus (18) 18
precursor cell lymphoblastic leukemia-lymphoma - genetics (18) 18
bcr-abl1 (17) 17
follow-up (17) 17
hematology, oncology and palliative medicine (17) 17
cml (16) 16
drug resistance, neoplasm (16) 16
pyrimidines - administration & dosage (16) 16
tyrosine kinase inhibitor (16) 16
care and treatment (15) 15
expression (15) 15
antineoplastic agents (14) 14
chronic-phase (14) 14
disease-free survival (14) 14
myeloid leukemia (14) 14
protein-tyrosine kinases - antagonists & inhibitors (14) 14
tyrosine kinase (14) 14
analysis (13) 13
bcr-abl mutations (13) 13
kinases (13) 13
protein-tyrosine kinase (13) 13
recommendations (13) 13
research (13) 13
acute lymphoblastic-leukemia (12) 12
follow-up studies (12) 12
fusion proteins, bcr-abl - antagonists & inhibitors (12) 12
gimema working party (12) 12
kinase domain mutations (12) 12
mesylate (12) 12
philadelphia chromosome (12) 12
piperazines - administration & dosage (12) 12
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (12) 12
reverse transcriptase polymerase chain reaction (12) 12
cancer research (11) 11
gene expression (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - mortality (11) 11
molecular response (11) 11
philadelphia-chromosome (11) 11
retrospective studies (11) 11
stem cells (11) 11
time factors (11) 11
antimitotic agents (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
clinical resistance (10) 10
domain mutations (10) 10
drug therapy (10) 10
leukemia, myelogenous, chronic, bcr-abl positive - pathology (10) 10
mutations (10) 10
neoplasms (10) 10
protein kinase inhibitors - pharmacology (10) 10
acute lymphoblastic leukemia (9) 9
cell biology (9) 9
cytogenetic responses (9) 9
fusion proteins, bcr-abl - metabolism (9) 9
interferon-alpha (9) 9
minimal residual disease (9) 9
patients (9) 9
polymerase-chain-reaction (9) 9
remission induction (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 25, pp. 4204 - 4210
Journal Article
Leukemia, ISSN 0887-6924, 09/2015, Volume 29, Issue 9, pp. 1823 - 1831
For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised... 
CHRONIC MYELOGENOUS LEUKEMIA | 400 MG | 1ST-LINE TREATMENT | EARLY MOLECULAR RESPONSE | EARLY INTERVENTION | BCR-ABL1 TRANSCRIPT LEVELS | ONCOLOGY | DIAGNOSED CHRONIC-PHASE | CYTOGENETIC RESPONSE | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | HEMATOLOGY | Prognosis | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Imatinib Mesylate - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Time Factors | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Imatinib Mesylate - administration & dosage | Aged, 80 and over | Adult | Female | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Treatment Outcome | Retreatment | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Adolescent | Aged | Chronic myeloid leukemia | Research | Drug therapy | Oncology, Experimental | Cancer | Tyrosine | Imatinib | Motivation | Risk groups | Myeloid leukemia | Leukemia | Cytogenetics | Remission | Kinases | Protein-tyrosine kinase | Optimization
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5202 - 5207
Journal Article
Blood, ISSN 0006-4971, 07/2014, Volume 124, Issue 4, pp. 469 - 471
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2006, Volume 12, Issue 24, pp. 7374 - 7379
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 12/2019, Volume 20, Issue 24, p. 6141
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article